ABSTRACT
Objective To analyze the status and its factors associated with HIV/AIDS“90-90-90”-treatment-target in Shandong province,China.Methods Data regarding testing,treatment on HIV/AIDS in Shandong province by December 31,2015 was collected.Chi-square test and logistic regression model were used to analyze related factors associated with the “90-90-90”-treatment-target.Results Of the 11 700 estimated HIV/AIDS,61.2％ were diagnosed,of whom 74.4％ had received Highly active antiretroviral therapy (HAART).More than 80％ of the HIV/AIDS on HAART reached the criteria on viral suppression.HIV/AIDS infected by homosexual contacts were less likely to seek for diagnosis (P＜0.05).HIV/AIDS lived in Qingdao city (OR=1.30,95％CI:1.05-1.60),Yantai city (OR=1.53,95％CI:1.02-2.31) and Weihai city (OR=1.96,95％CI:1.07-3.58) were more likely to receive HAART.HIV/AIDS patients that infected through homosexual or (OR=O.12,95％CI:0.06-0.24) or heterosexual contacts (OR =0.13,95 ％CI:0.07-0.26),through injecting drug use (OR =0.08,95％CI:0.03-0.17) or being diagnosed at the custodial institutions (OR=0.29,95％CI:0.21-0.41)were less likely to receive HAART.HIV/AIDS patients who received HAART at medical institutions (OR=1.81,95％ CI:1.05-3.47) were more likely to meet the level of Viral load (VL) suppression.However,those who were infected through homosexual (OR=0.43,95％ CI:0.25-0.75) or heterosexual contacts (OR =0.49,95％CI:0.28-0.81) or diagnosed at the custodial institutions (OR =0.48,95％CI:0.28-0.80) were less likely to meet the criteria set for VL suppression.Conclusions There was a gap between the status of testing/treatment and the target on HIV/AID “90-90-90”-treatment,especially on the target set for testing,in Shandong Province.Both HIV testing and comprehensive care services need to be strengthened.
ABSTRACT
Objective To analyze the status and its factors associated with HIV/AIDS“90-90-90”-treatment-target in Shandong province,China.Methods Data regarding testing,treatment on HIV/AIDS in Shandong province by December 31,2015 was collected.Chi-square test and logistic regression model were used to analyze related factors associated with the “90-90-90”-treatment-target.Results Of the 11 700 estimated HIV/AIDS,61.2％ were diagnosed,of whom 74.4％ had received Highly active antiretroviral therapy (HAART).More than 80％ of the HIV/AIDS on HAART reached the criteria on viral suppression.HIV/AIDS infected by homosexual contacts were less likely to seek for diagnosis (P＜0.05).HIV/AIDS lived in Qingdao city (OR=1.30,95％CI:1.05-1.60),Yantai city (OR=1.53,95％CI:1.02-2.31) and Weihai city (OR=1.96,95％CI:1.07-3.58) were more likely to receive HAART.HIV/AIDS patients that infected through homosexual or (OR=O.12,95％CI:0.06-0.24) or heterosexual contacts (OR =0.13,95 ％CI:0.07-0.26),through injecting drug use (OR =0.08,95％CI:0.03-0.17) or being diagnosed at the custodial institutions (OR=0.29,95％CI:0.21-0.41)were less likely to receive HAART.HIV/AIDS patients who received HAART at medical institutions (OR=1.81,95％ CI:1.05-3.47) were more likely to meet the level of Viral load (VL) suppression.However,those who were infected through homosexual (OR=0.43,95％ CI:0.25-0.75) or heterosexual contacts (OR =0.49,95％CI:0.28-0.81) or diagnosed at the custodial institutions (OR =0.48,95％CI:0.28-0.80) were less likely to meet the criteria set for VL suppression.Conclusions There was a gap between the status of testing/treatment and the target on HIV/AID “90-90-90”-treatment,especially on the target set for testing,in Shandong Province.Both HIV testing and comprehensive care services need to be strengthened.
ABSTRACT
Background: Chilean AIDS Cohort is the oldest and extensive in Latin America and one of most numerous and with longer follow up time to international level. Records information from 14,873 patients out of approximately 22,000 in antiretroviral therapy in the public system and its results have allowed to know the national reality and have contributed to the adoption of public policies. Aim: To describe the demographic, clinical and immunological characteristics of patients who have started ART in Chile and its evolution over the past 15 years. Patients and Methods: The cases were stratified by five-year periods: 2001-2005, 2006-2010 and 2011-2015. The data analysis included calculating proportions, their respective confidence intervals 95% and X² test for significance analysis was applied. Results: 17.4% of patients starting ART are women and the proportion has remained relatively constant. The highest proportion of new HIV cases are 30 and 39 years old, nevertheless the layer of 15-29 years demonstrates a significant increase from 21.7 to 36.4% in 2011-2015 especially in men. 12.1% of new cases are older than 50 years old with a stable trend over time; however, women over 50 have increased from 11.0 to 15.6%. Antiretroviral therapy initiation with CD4+ T lymphocytes less than 200 cells/mm³ has decreased from 79.7 to 42.4% and in stage C from 45.4 to 22.6%. Late presentation to antiretroviral therapy is higher in men but this gap has narrowed in the last five years. Pneumocystis jiroveci, wasting syndrome, tuberculosis, Kaposi’s sarcoma and esophageal candidiasis are the most common opportunistic diseases without significant changes in the three-year periods analyzed. In the last five years, 15.5% of opportunistic diseases occurs in patients with CD4+ TL > 200 cells/mm3. Discussion: Despite the limitations of observational studies present report describes the characteristics and evolution of the epidemics in Chile in the last 15 years. The infection occurs at younger ages in men, whereas in women there is an increase over 50 years old. Despite advances in treatment access have reduced late presentation to therapy, important challenges remain to achieve more timely initiation of antiretroviral therapy in accordance with WHO 90-90-90 goals.
Introducción: La Cohorte Chilena de SIDA es la más antigua y extensa de Latinoamérica y una de las más numerosas y con mayor tiempo de seguimiento a nivel internacional. Registra información de 14.873 pacientes de los aproximadamente 22.000 en TARV en el sistema público y sus resultados han permitido conocer la realidad nacional y han contribuido a la adopción de políticas públicas. El objetivo de este estudio es describir las características demográficas, clínicas e inmunológicas de los pacientes que han comenzado TARV en Chile y su evolución en los últimos 15 años. Pacientes y Métodos: Los casos fueron estratificados por quinquenios: 2001-2005, 2006-2010 y 2011-2015. El análisis de los datos incluyó el cálculo de proporciones, sus respectivos intervalos de confianza 95% y se aplicó test de X² para análisis de significación. Resultados: El 17,4% de los casos que inician TARV corresponde a mujeres y la proporción se ha mantenido relativamente constante. Por edad, destaca el grupo de adultos entre 30 y 39 años aunque el estrato de 15-29 años evidencia un importante aumento desde 21,7 a 36,4% en 2011-2015, especialmente en hombres. Un 12,1% del total de los inicios de TARV son mayores de 50 años con una tendencia estable en el tiempo; sin embargo, las mujeres mayores de 50 años han aumentado de 11,0 a 15,6%. El inicio de TARV con LT CD4 menor de 200 céls/mm³ ha disminuido desde 79,7 a 42,4% y en etapa C desde 45,4 a 22,6%. La presentación tardía a TARV es mayor en hombres pero esta diferencia se ha reducido en el último quinquenio. Neumonía por Pneumocystis jiroveci, síndrome consuntivo, tuberculosis, sarcoma de Kaposi y candidiasis esofágica son las enfermedades oportunistas más frecuentes sin cambios significativos en los tres quinquenios analizados. En el último quinquenio, 15,5% de las enfermedades oportunistas se presenta en pacientes con LT CD4 > 200 céls/mm³. Discusión: Pese a las limitaciones de los estudios observacionales el presente reporte describe las características y evolución de la epidemia en Chile en los últimos 15 años. La infección se presenta a edades más jóvenes en hombres, mientras que en mujeres hay un aumento en mayores de 50 años. Pese a los avances en acceso a tratamiento que han permitido reducir la presentación a tardía a terapia, aún persisten importantes desafíos para alcanzar un inicio de TARV más oportuno, en concordancia con las metas 90-90-90 de OMS.